Site Map
Pages
-
About
- Contact us
- CQDM
- Equity, Diversity and Inclusion (EDI)
- Governance
-
Team
- Alexandre Morizot
- Alysia Melnychuk
- Annie Bernier
- Catherine-Alexandra Grégoire
- Diane Gosselin
- Dorothy Josué
- Fanny Guimont-Desrochers
- Jeanne Ouellet-Ayotte
- Jesse Paterson
- Julia Serafino
- Marina Luginina
- Mathieu Paquette
- Morgane Regniez
- Rebeca Baca-Diaz
- Samar Khoury
- Sandra Constantin
- Sandrine Campeau
- Simon Fournier
- Véronique Dugas
- Walande Corrier
- Xavier Linker
- Who We Are ?
-
Achievement
-
Funded Projects
- A 150-plex affinity proteomics platform for high throughput and high content phenotypic cell screening
- A Blood-Brain Barrier Carrier Platform for Delivery of Multiple Classes of Therapeutics for Treating CNS Diseases
- A Drug Screening Platform to Increase Protein Expression Levels for Treatment of Neurological Disorders
- A new platform to Assess Antigen Destruction and Evaluate the Efficacy of Immunotherapies and Vaccines
- A novel immunotherapy based on genetically modified hematopoietic stem cells as a new hope for treating glioblastoma, an aggressive cancerous tumor of the brain
- A novel phage-based screening technology for antiviral
- A Novel Platform Combining Transcriptomics and Interaction Proteomics to Better Define Personalized Medicine in Cancer
- A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers
- A Screening Technology to Improve the Discovery of Function-Modifying Antibodies Against Membrane Protein Targets
- A Zebrafish-Based Platform for Nuclear Receptor Drug Screening and Pathway Discovery in Metabolic Disease and Cancer
- Acting on membrane protein-protein interactions: Mammalian Membrane Two Hybrid (MaMTH) as an Innovative Technology for Drug Discovery Against Protein- Protein Interactions
- Alzheimer’s Disease Mouse Model Characterization: Correlation Between MRI and ex vivo Immunohistochemistry
- Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia
- Artificial intelligence-powered platform for analyzing the success of clinical trials and interpreting risk factors
- Artificial Liver for Safer and more Effective Drugs: Three-Dimensional Liver Tissue Models for High-Throughput Screening of the Efficacy and Hepatotoxicity of Drugs
- Automated Zebrafish High Throughput Drug Screening Platform: An Automated Zebrafish High Throughput Technology to Accelerate in vivo Screening of Small Molecules in Disease Models
- Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacterial infections
- Biomarkers Discovery in Diabetes: New Biomarkers for Measurement of Early Stage Diabetes Disease and for Prediction of Response to Therapy
- Blood-based biomarkers to diagnose neuroendocrine tumors, follow disease progression and identify new therapeutic targets
- Catecholamine-Regulated Protein 40 (CRP40) as a New Candidate Biomarker for Early Diagnosis of Parkinson’s Disease
- Circumventing the need for predictive biomarkers in personalized ovarian cancer therapies: empirical chemosensitivity testing using a microfluidics-based multiplex platform
- Computational and machine learning approaches to improve design and screening of peptides in drug discovery
- Cycloinformatics: A Platform to Rapidly Produce Macrocyclic New Chemical Entities to inhibit Protein- Protein Interactions
- Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases
- Defining the Rules That Will Enhance the Cell Permeability and Oral Bioavailability of Macrocycles
- Design and Characterization of Feldan Shuttle Peptides and Derivatives as Pulmonary Delivery Agent
- Detection of Molecular Interaction Field Similarities for the Rational Drug Design of Multi-Functional Inhibitors
- Developing an evidence-based approach to diagnose and treat adults with a history of concussion
- Developing marine worm M101 hemoglobin extract for cancer therapy
- Developing New Alzheimer’s Therapeutics Using a Novel Carrier That Can Cross the Blood-Brain Barrier
- Developing open access protein degradation tools for drug discovery
- Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population
- Development of a high throughput 3D microphysiological platform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders
- Development of a high throughput bioprinted 3D human tumor microenvironment assay that recreates immune “hot” and “cold” tumors
- Development of a new class of oral and highly potent non-statin LDL-cholesterol lowering therapeutics for patients at high cardiovascular risk
- Development of a New Matrix for Pancreatic Islets Culture and its Validation in a Bioartificial Pancreas
- Development of a personalized living chicken embryo avatar model to predict chemotherapeutic drug sensitivity/resistance
- Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine
- Development of immunotherapy for bladder cancer using IMV’s drug delivery platform
- Development of inhibitors for CUX1 and PARG, two novel therapeutic targets for hard-to-treat breast cancers
- Development of novel biologic inhibitors of Semaphorin3A for the treatment of retinal vascular diseases.
- Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia
- Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias
- Development of pharmacological correctors for Alpha-1 antitrypsin deficiency (ATD) using VIPER
- Dimer Interfering peptides (DIPs): A novel platform for targeting the immunosuppressive functions of prototypic galectins
- Discovery of analgesic drugs targeting the acid-sensing ion channel family
- Engineering Endogenous Vesicles as a Drug Delivery Platform to Inhibit Gene Expression Using microRNAs and Silencing RNAs
- Establishing a world-class biophysics platform that will enable and accelerate the discovery of leads for launching drug-discovery programs
- Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs
- Facilitating Anti-Cancer Drug Discovery with Selective Inhibitors to Modulate the Protein Ubiquitination Process
- First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies
- FlAsH-Walk Mapping: An Innovative Step-by-Step Approach to G Protein-Coupled Receptor Conformation Cartography
- Fragment-Based Lead Discovery: Bridging the Gap Between Screening and Hit-to-Lead Medchem using NMR Affinity Ranking
- Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds
- Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds
- Identification of T Cell Receptor Somatic Mutations Driving Autoimmunity in Human Rheumatoid Arthritis
- Identification of Tumor Specific Antigens to Develop Therapeutic Vaccines Against Acute Myeloid and Lymphoid Leukemias
- In vivo demonstration of potency to improve impaired efferocytosis and control inflammation related to Systemic Lupus Erythematosus (SLE)
- In-vivo Solid Phase Microextraction Integrated with Mass Spectrometry Platform for Untargeted and Targeted Investigation of the Brain
- Inducible human pluripotent stem cells to better understand and treat Parkinson’s disease and ALS
- Inducible Mouse Models to Accelerate Drug Development for Parkinson’s Disease and Other Synucleinopathies
- Innervated, Vascularised and Immunocompetent Human Skin Model for Screening the Sensitization Potential of Chemicals
- Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma
- Innovative Optical Imaging and Bio-Simulation Platforms to Accelerate Central Nervous System Drug Discovery
- Integrating Tumour-Microenvironment Biomarkers to Improve Diagnostic and Facilitate Targeted Breast Cancer Therapy
- Intracellular delivery of antibodies and peptides using a peptide-based technology
- IPPER, the Integrated Platform for the Pharmacology of the Endoplasmic Reticulum and protein trafficking diseases
- Leveraging genomics and proteomics to identify novel biomarkers and drug targets for diabetic kidney disease
- Live Cell Imaging System for Protein-Protein Interactions: Multiplexing Fluorescence Lifetime Imaging: a rapid HCS system to study protein-protein interactions in live cells
- Macrocyclic peptides as the next-generation immuno-oncology therapeutics
- Magnetically Guided Bacteria to Specifically Deliver Anti-Cancer Agents to Colorectal Cancer Sites
- Mapping Genetic Interactions: A Path to Discover Efficacious Drug Targets
- Monitoring Conformational Changes in Channel Proteins: A Novel Approach for Rapid Screening of Ion Channel Hits
- Monitoring the Signaling Pathways of G Protein Coupled Receptors in Living Animals to Accelerate Drug Discovery
- Multimodal digital biomarkers for the identification of companion diagnostic tools in cardiovascular diseases.
- New GPCR-Specific Biosensor Technology to Monitor Cellular Events Associated with Drugs Efficacy and Side Effects
- New Processes Mimicking the Spray drying technique for the Preparation of Thermally Stable Vaccines
- Non-Invasive Diagnostic Test Using Electroretinography for Profiling Patients with Schizophrenia and Bipolar Disorders
- Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer
- Novel in silico-assisted Platform to Rapidly Enhance Specificity and Affinity of Therapeutic Antibodies Against Their Targets
- Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
- Novel Non-Invasive Laser-Assisted Intraocular Drug Delivery System for an Efficient and Selective Gene Transfer Therapy
- Novel p53-activiting MDM2 inhibitor oncology platform therapy
- Optimizing KBTBD4-CoREST1 acting compounds for tissue rejuvenation
- Optimizing the monitoring of patients with DLBCL
- Personalized Medicine 2.0: Integrated Functional and Genomic Profiling to Determine Optimum Combination Therapy for Cancer Patients
- Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment
- Platform for the enrichment of circulating tumor cells (CTCs) for characterization and sensitivity to anti-cancer drugs
- Platform to target small-molecule therapeutics to bone – Novel prodrugs to selectively deliver therapeutics to bone
- Pre-clinical design of a novel targeted and personalized treatment against sortilin-positive triple negative breast cancers
- Prospective evaluation of the ONETest™ targeted metagenomic platform to identify respiratory tract pathogens for precise diagnosis and clinical trial recruitment
- PulmoBind: A New Non-Invasive Marker for the Early Diagnosis of Patients with Pulmonary Hypertension
- Quantification of Her2 expression in breast cancer tumors using plasmonic nanoparticles as protein markers
- QUO2 MRI: Quantitative Measurement of Metabolic and Vascular Anomalies in the Brain of Alzheimer’s Disease Patients
- RecyTag technology for extended half-lives of small biologics
- Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers
- Selectomics to monitor and predict the emergence of resistance to antibiotics by using the human microbiome
- ShARP: Screenable Assays for RNA-Binding Proteins Involved in Brain Disorders
- Synthetic lethality platform to discover, test and validate new therapeutic treatment options for cancer
- Targeting the Right Cells: Human MiniPromoters for Restricted Gene Expression in Specific Cells of the Eyes
- Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine
- The application of 3D models to assess the role of microglia in neurodegenerative disorders
- The Encapsulated Liver Tissue as a treatment for acute liver failure: proof-of-concept efficacy and safety in large animals using liver organoids composed of primary cells
- The eye: a window to the brain – Detection of Alzheimer’s Disease in the Prodromal Stage from Non-Invasive Hyperspectral Retinal Images
- Topic nanovectors for targeted gene therapy of cutaneous psoriasis
- Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers
- Treatment of Hirschsprung disease by rectal administration of neurotrophic factors.
- TRIple negative breast Cancer markers In liquid biopsies using Artificial intelligence (TRICIA study)
- Unlocking a class of challenging drug targets using a next generation screening and lead development platform technology
- Using Patient’s Blood to Develop a Sensory Neuron-Based Platform to Treat Chemotherapy-Induced Peripheral Neuropathy
- Validation of KQ-791 in combination immunotherapies cancer models
- VIPER, the lentiviral IPPER platform for drug discovery in trafficking diseases. IPPER-accelerated development of pharmacological correctors for cystic fibrosis
- VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles
- YCharOS Inc. (Antibody Characterization through Open Science): A platform enabling neuroscience target validation
- Zebrafish High Throughput Screening Platforms for Nuclear Receptor-Related Drug Discovery and Pathway Elucidation
- Structuring Initiatives
- Success Story
-
Funded Projects
- Careers
- Cookie policy
- Funding R&D
- Members and Partners
-
News and Events
- $1.5M to accelerate drug discovery within the Quebec-Ontario Life Sciences Corrido
- $50 million to support biotech companies
- 15th of CQDM.
- 2021 Sweet Pharma Day Winner is HDAX Therapeutics
- 2023 Sweet Biopharma Day Winner is Epitopea!
- 2024 OBIO Investment Summit
- 2nd Annual Gordon Shore Prize - Postdoctoral Internships in the Biopharmaceutical Industry
- 2nd Annual Gordon Shore Prize – Call for Proposal to Private Companies
- 2nd edition of Connect-Pharma : Pitch day.
- 3rd edition of Connect-Pharma : Pitch day.
- 4,000 subscribers to our LinkedIn page
- 48Hour Discovery and Merck initiate drug discovery project - Project funded through CQDM Quantum Leap program
- 4th edition of Sweet Biopharma Day – Call for entries now open
- A 150-plex affinity proteomics platform for high throughput and high content phenotypic cell screening
- A 5th competition for the Quebec/France Program
- A Blood-Brain Barrier Carrier Platform for Delivery of Multiple Classes of Therapeutics for Treating CNS Diseases
- A Drug Screening Platform to Increase Protein Expression Levels for Treatment of Neurological Disorders
- A genetic test to predict diabetic nephropathy in Type 2 diabetes patients
- A new partnership between CQDM, the Canadian Cancer Society, the Cole Foundation and Oncopole to support pediatric cancer research
- A new platform to Assess Antigen Destruction and Evaluate the Efficacy of Immunotherapies and Vaccines
- A novel phage-based screening technology for antiviral
- A Novel Platform Combining Transcriptomics and Interaction Proteomics to Better Define Personalized Medicine in Cancer
- A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers
- A project funded by CQDM redefines the treatment of cancer
- A research project originally funded by CQDM and Brain Canada leads to a new partnership between the Centre for Drug Research and Development (CDRD), the Montreal Neurological Institute and Hospital at McGill University (MNI), and Merck
- A Screening Technology to Improve the Discovery of Function-Modifying Antibodies Against Membrane Protein Targets
- A Zebrafish-Based Platform for Nuclear Receptor Drug Screening and Pathway Discovery in Metabolic Disease and Cancer
- Accelerating the transition from idea to market - Submission of the RSRI brief
- Access funding for your RD projects with the support of conscience and CQDM
- Acting on membrane protein-protein interactions: Mammalian Membrane Two Hybrid (MaMTH) as an Innovative Technology for Drug Discovery Against Protein- Protein Interactions
- ADRIQ 2022 Award – Warmest congratulations to Steven LaPlante of INRS and NMX Research and Solutions, winners of the Industrial Sectoral Research Group Award (RSRI) presented by CQDM!
- ADRIQ* 2021 AWARD – CQDM congratulates Feldan Therapeutics for receiving the 2021 ADRIQ RSRI (regroupements sectoriels de recherche industrielle) award.
- AI and drug development
- Ali Tehrani appointed on CQDM’s Board of Directors
- Alzheimer’s Disease Mouse Model Characterization: Correlation Between MRI and ex vivo Immunohistochemistry
- Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics
- Amgen becomes a new member of CQDM to further the development of cutting-edge drug discovery
- Announcement - The therapeutic potential of a marine oxygen carrier
- Announcement - World Cancer Day
- Announcement – Development of a New Diagnostic Technique for Targeted Treatment of Breast Cancer
- Announcement – Innovative Treatments for Diabetic Kidney Disease
- Announcement – Rare Disease Day
- Announcement – Research project promoting cellular rejuvenation
- Announcement of a new funding from the Government of Canada
- Announcement of an investment of close to $8 million dollars in biopharmaceutical research in Québec
- Appointments to the CQDM Board of Directors.
- Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia
- Artificial Liver for Safer and more Effective Drugs: Three-Dimensional Liver Tissue Models for High-Throughput Screening of the Efficacy and Hepatotoxicity of Drugs
- Automated Zebrafish High Throughput Drug Screening Platform: An Automated Zebrafish High Throughput Technology to Accelerate in vivo Screening of Small Molecules in Disease Models
- Axelys and the sector-based industrial research clusters are joining forces to boost innovation in Quebec for the benefit of research centers, businesses and society.
- Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacterial infections
- Become a CQDM Member.
- Bernard Massie and Cameron Black appointed to CQDM’s Scientific Advisory Board
- Biomarkers Discovery in Diabetes: New Biomarkers for Measurement of Early Stage Diabetes Disease and for Prediction of Response to Therapy
- BIOQuébec, QCDD, NEOMED Institute, Montréal InVivo and Rx&D call on political parties to spell out their intentions and priorities for the life science sector
- Blood-based biomarkers to diagnose neuroendocrine tumors, follow disease progression and identify new therapeutic targets
- Call for Applications for the Gordon Shore Prize - Internships for new graduates
- Call for collaborative research projects on precision care in oncology
- Call for ideas: driving innovation in personalized medicine through translational research and collaboration.
- Call for Proposal to Private Companies - Post-Diploma Internships Co-Funded through the Gordon Shore Prize
- Call of ideas : Driving innovation in personalized medicine through translational research and collaboration
- Canadian Cancer Society and CQDM announce a partnership of $5 million for breast cancer research in Quebec
- Catecholamine-Regulated Protein 40 (CRP40) as a New Candidate Biomarker for Early Diagnosis of Parkinson’s Disease
- Circumventing the need for predictive biomarkers in personalized ovarian cancer therapies: empirical chemosensitivity testing using a microfluidics-based multiplex platform
- Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D
- Collaborative R&D – a Catalyst of Innovation for Biopharmaceutical Companies
- Communicating Life Sciences to the Public: Winners of “Tweete tes neurones!” challenge pitch in
- COMMUNICATIONS AND MARKETING COORDINATOR
- Competition results 2008-2009 (letter of intent)
- Computational and machine learning approaches to improve design and screening of peptides in drug discovery
- Congrats Sandra!
- Congratulations Alexandre Morizot.
- Congratulations Sandrine Campeau
- Congratulations Université Laval
- Connect-Bio : Collaborations to Propel Innovation in Neuroscience
- Connect-Pharma: Pitch Day
- Contribution from the MEI ($3.3M) allows CQDM to support 5 biopharmaceutical research projects ($15.5M)
- CQDM 2014 Activity Report: A year of partnerships
- CQDM 5 years already and many achievements!
- CQDM acknowledges the success of the Forum Québécois des Sciences de la Vie which was organized by the government of Quebec
- CQDM and a group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec
- CQDM and Brain Canada Inject $1 M in Top BC Biotech Firm AbCellera to Advance Discovery Platform for Next-Generation Antibody Therapeutics
- CQDM and Defence Therapeutics fund the development of a new cancer vaccine platform
- CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Supportive Platform Enabling the Development of RNA-based Immunotherapies
- CQDM and Génome Québec joins to launch le Défi « Tweete tes neurones »
- CQDM and NanoGene Therapeutics Fund the Development of a Treatment for Psoriasis
- CQDM and OCE co-fund a promising research collaboration in neuroscience
- CQDM and Sanofi Canada partner to accelerate drug discovery
- CQDM and SPM Therapeutics fund a study carried out by Professor Boilard at the CHU de Québec-Université Laval to develop a treatment for systemic lupus erythematosus
- CQDM and the Canadian Cancer Society commend Theratechnologies and UQAM for their success in developing a new therapy against the most aggressive form of breast cancer
- CQDM and the Massachusetts Life Sciences Center announce a new international partnership program
- CQDM and the Sorintellis Group fund the development of an AI-powered platform to mitigate clinical trial risks
- CQDM and YCharOS Inc. fund the development of an antibody characterization platform to facilitate R&D and propel the development of new drugs
- CQDM announces a new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec
- CQDM announces funding to develop a test to predict disease progression in patients infected with COVID-19
- CQDM Announces New Member to its Precompetitive Research Consortium to Accelerate Drug Discovery: Janssen Inc.
- CQDM Announces the Arrival of Carl Baillargeon in its Team
- CQDM announces the creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies
- CQDM announces the creation of training programs to meet the needs of the RNA therapeutics industry
- CQDM appoints Brian Underdown as the Chair of its Scientific Advisory Board (SAB) and nominates 3 new SAB members
- CQDM Awards a Grant to Centre de Recherche du CHU de Québec-Université Laval ...
- CQDM becomes a shareholder of Mesentech to support the validation of a highly promising bone-targeting drug delivery technology
- CQDM Congratulates Perceiv AI, DalCor Pharmaceuticals, and Dr. Tardif for Winning the 2024 ADRIQ RSRI Innovation Award
- CQDM congratulates recipients of the second call for projects from the Fonds d'accélération des collaborations en santé (FACS)
- CQDM Congratulates Theratechnologies and Professor Borhane Annabi from UQAM.
- CQDM funds a collaborative research project between the RI-MUHC and Divocco AI to develop an artificial intelligence-driven technology that improves regional anesthesia
- CQDM Funds a Project Aiming to Elucidate the Effets of Psilocybin on Neuronal Circuits in Order to Treat Depression
- CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation
- CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation
- CQDM Funds Four Projects to Transform Innovation Into Promising Medical Solutions
- CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials
- CQDM grants $1.15 M in funding to Professor Yves St-Pierre’s team to develop a revolutionary immunotherapy against breast cancer
- CQDM initiates a unique collaboration with Merck, Pfizer and Biospective on Alzheimer’s disease
- CQDM invests $500,000 in Giiant Pharma, a Quebec-based pharmaceutical company with strong potential in gastroenterology
- CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies
- CQDM is proud to announce a new collaboration / broadcast / communication partnership with OBIO.
- CQDM is proud to announce an investment of $1.5 M in two collaborative projects from the Québec/Ontario corridor
- CQDM is proud to be part of Optina Diagnostics' success
- CQDM is proud to contribute to the success of Medicago and its partners, winners of the 2020 RSRI Innovation Award from ADRIQ
- CQDM is proud to present a new series of events: Connect-Pharma
- CQDM is proud to welcome our new Network Member: RNA Technologies and Therapeutics!
- CQDM is recruiting! Interested in a summer Internship position in Administration and Accounting? Apply now!
- CQDM joins forces with Neurasic Therapeutics, CSVS and the Louise and Alan Edwards Foundation to fund the development of a non-opioid analgesic
- CQDM nominates John Delaney and Jennifer Hamilton as Scientific Advisory Board members
- CQDM nominates Kuldeep Neote as Scientific Advisory Board member
- CQDM partners with D2R to enhance collaborations among researchers and industry in RNA research
- CQDM partners with GlycoNet to support innovative Glycomics research in Canada
- CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor
- CQDM portfolio company Mesentech secures new capital to bring lead product to clinical phase
- CQDM present at NeuroSphere
- CQDM receives funding of $ 11.7 M from the Federal Government
- CQDM receives the Innovation Price during the "Fête Champêtre 2010" of the Fondation Armand-Frappier
- CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet
- CQDM SynergiQc program now includes an additional section on breast cancer, in collaboration with the Canadian Cancer Society
- CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University
- CQDM to fund an international collaboration between Traffick Therapeutics, McGill University and the Lead Discovery Center
- CQDM to support a $1.1 M R&D project for Immune Biosolutions’ next-generation of anti-cancer treatment
- CQDM welcomes 3 new ''Network'' Members.
- CQDM Welcomes Eli Lilly Canada, A Leading Innovative Pharmaceutical Company, to Support the Explore Program
- CQDM welcomes its new member "Network" VVector Bio!
- CQDM welcomes Novartis as a new contributing member to the Explore Program
- CQDM welcomes the update of the Quebec Life Sciences Strategy
- CQDM welcomes two additional Pharma members, Boehringer Ingelheim and GlaxoSmithKline Inc.
- CQDM welcomes two new pharma members to its biopharmaceutical research consortium
- CQDM welcomes Zymeworks as a new member of CQDM’s biopharmaceutical consortium
- CQDM will be in Quebec City on October 10 to present its financing programs
- CQDM will partner with Feldan Therapeutics to support a $1.2M project, to improve a novel intra-cellular delivery technology
- CQDM will receive a grant from the BL-NCE to research better ways of developing and testing drugs that treat central nervous system diseases
- CQDM, Brain Canada and industry partners join forces to address unmet medical needs in the treatment of brain disorders
- CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the creation of a prize of excellence for graduate students in cancer research in memory of Professor Gordon Shore
- CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the two laureates of the 2019 Gordon Shore Prize
- CQDM, Feldan Therapeutics and Amgen fund development of innovative drug delivery technology to target lung diseases
- CQDM, HBHL, Corbin Therapeutics and Brain Canada award $1.5 M to McGill Prof. Philippe Gros
- CQDM, MEDTEQ+ and Montréal InVivo partner with IVADO to promote digital health innovation
- CQDM, the CCS and Theratechnologies grant $1.7M to UQAM in breast cancer research
- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
- CQDM's 2015 Activity Report: A toolbox of success
- Creation of a global hub for RNA-based therapies in Quebec
- Cycloinformatics: A Platform to Rapidly Produce Macrocyclic New Chemical Entities to inhibit Protein- Protein Interactions
- Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases
- Défi Tweete tes neurones! - Optimum Vice President and general manager, Isabelle Perras, agrees to act as president of the jury
- Defining the Rules That Will Enhance the Cell Permeability and Oral Bioavailability of Macrocycles
- Design and Characterization of Feldan Shuttle Peptides and Derivatives as Pulmonary Delivery Agent
- Detection of Molecular Interaction Field Similarities for the Rational Drug Design of Multi-Functional Inhibitors
- Developing New Alzheimer’s Therapeutics Using a Novel Carrier That Can Cross the Blood-Brain Barrier
- Developing open access protein degradation tools for drug discovery
- Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population
- Development of a high throughput 3D microphysiological platform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders
- Development of a high throughput bioprinted 3D human tumor microenvironment assay that recreates immune “hot” and “cold” tumors
- Development of a machine learning-based in-process quality monitoring technology for plants during vaccine manufacturing
- Development of a new class of oral and highly potent non-statin LDL-cholesterol lowering therapeutics for patients at high cardiovascular risk
- Development of a New Matrix for Pancreatic Islets Culture and its Validation in a Bioartificial Pancreas
- Development of a personalized living chicken embryo avatar model to predict chemotherapeutic drug sensitivity/resistance
- Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine
- Development of immunotherapy for bladder cancer using IMV’s drug delivery platform
- Development of inhibitors for CUX1 and PARG, two novel therapeutic targets for hard-to-treat breast cancers
- Development of novel biologic inhibitors of Semaphorin3A for the treatment of retinal vascular diseases.
- Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia
- Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias
- Development of pharmacological correctors for Alpha-1 antitrypsin deficiency (ATD) using VIPER
- Diane Gosselin appointed President and Chief Executive Officer of CQDM
- Dimer Interference: A novel Approach to Develop Galectin-7-Specific Inhibitors to treat Triple-Negative Breast Cancer
- Discovery of analgesic drugs targeting the acid-sensing ion channel family
- Domain Therapeutics, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology
- Drive innovation and performance by integrating equity, diversity, and inclusion
- Drug-enabling technology innovations get boost through OCE-CQDM Life Sciences R&D challenge
- Encycle Therapeutics Launches Ground-Breaking Chemistry Platform
- Encycle Therapeutics working with major pharmaceutical companies to design rules for drugs meant to be swallowed
- Engineering Endogenous Vesicles as a Drug Delivery Platform to Inhibit Gene Expression Using microRNAs and Silencing RNAs
- Establishing a world-class biophysics platform that will enable and accelerate the discovery of leads for launching drug-discovery programs
- Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs
- Facilitating Anti-Cancer Drug Discovery with Selective Inhibitors to Modulate the Protein Ubiquitination Process
- First research project to be funded under the Canada/Germany Program
- First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies
- FlAsH-Walk Mapping: An Innovative Step-by-Step Approach to G Protein-Coupled Receptor Conformation Cartography
- Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences
- Fragment-Based Lead Discovery: Bridging the Gap Between Screening and Hit-to-Lead Medchem using NMR Affinity Ranking
- Funding activities carried out in companies that are part of collaborative R&D Projects in Artificial Intelligence
- Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds
- Germany and Canada join forces to enhance biopharmaceutical R&D internationally
- GlycoNet and CQDM collaborate to boost drug discovery and develop new health solutions for Canadians
- GRANTS MANAGEMENT AND COMPLIANCE COORDINATOR
- Health Innovation: Investing Now to Face the Crises of Tomorrow
- Hope on the horizon for hard-to-treat breast cancers
- Identification of T Cell Receptor Somatic Mutations Driving Autoimmunity in Human Rheumatoid Arthritis
- Identification of Tumor Specific Antigens to Develop Therapeutic Vaccines Against Acute Myeloid and Lymphoid Leukemias
- IMV and CRCHU de Québec-U Laval Collaboration Awarded a CQDM Grant to Develop First-in-class Dual Target T cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
- In vivo demonstration of potency to improve impaired efferocytosis and control inflammation related to Systemic Lupus Erythematosus (SLE)
- In-vivo Solid Phase Microextraction Integrated with Mass Spectrometry Platform for Untargeted and Targeted Investigation of the Brain
- Inducible human pluripotent stem cells to better understand and treat Parkinson’s disease and ALS
- Inducible Mouse Models to Accelerate Drug Development for Parkinson’s Disease and Other Synucleinopathies
- Industrial research clusters congratulate new Minister of the Economy and Innovation
- Innervated, Vascularised and Immunocompetent Human Skin Model for Screening the Sensitization Potential of Chemicals
- Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma
- Innovative Optical Imaging and Bio-Simulation Platforms to Accelerate Central Nervous System Drug Discovery
- Integrating Functional and Genomic Profiling for Optimal Combination Therapies for Cancer Patients
- Integrating Tumour-Microenvironment Biomarkers to Improve Diagnostic and Facilitate Targeted Breast Cancer Therapy
- Intracellular delivery of antibodies and peptides using a peptide-based technology
- IPPER, the Integrated Platform for the Pharmacology of the Endoplasmic Reticulum and protein trafficking diseases
- JOB OFFER - ADMINISTRATIVE ASSISTANT
- JOB OFFER - DIRECTOR SCIENTIFIC AFFAIRS
- JOB OFFER - SENIOR DIRECTOR ACCOUNTING AND FINANCE
- Julie Martineau appointed as Senior Director, Communications and Corporate Development of CQDM
- Life sciences and health technologies should be the focus of Quebec’s next research and innovation policy
- Live Cell Imaging System for Protein-Protein Interactions: Multiplexing Fluorescence Lifetime Imaging: a rapid HCS system to study protein-protein interactions in live cells
- Lyonbiopôle, CQDM and Alsace BioValley organize the first joint networking event in Lyon to encourage the emergence of French-Quebec projects.
- Macrocyclic peptides as the next-generation immuno-oncology therapeutics
- Magnetically Guided Bacteria to Specifically Deliver Anti-Cancer Agents to Colorectal Cancer Sites
- Make a difference! Job Opportunity: controller
- Mapping Genetic Interactions: A Path to Discover Efficacious Drug Targets
- Mario Chevrette appointed Vice President, Scientific Affairs of CQDM
- McGill, industry, CQDM and Brain Canada collaborate for drug discovery
- Merck Canada Invests $5 Million in Quebec Consortium for Drug Discovery to Support Biopharmaceutical Research
- Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in Life Sciences
- Merck Canada reaffirms its commitment to CQDM with $3M in funding to support biopharmaceutical innovation.
- Michel Goldman appointed member of CQDM’s Board of Directors
- Monitoring Conformational Changes in Channel Proteins: A Novel Approach for Rapid Screening of Ion Channel Hits
- Monitoring the Signaling Pathways of G Protein Coupled Receptors in Living Animals to Accelerate Drug Discovery
- Multimodal digital biomarkers for the identification of companion diagnostic tools in cardiovascular diseases.
- Neomabs Biotechnologies, a company dedicated to developing new immunotherapies for cancer treatment launches in Montreal
- Neuro-CERVO Alliance partners with Simmunome, a Montreal-based artificial intelligence company
- New appointments to CQDM’s Board of Directors and Scientific Advisory Board
- New call for proposals under the Fonds d’accélération des collaborations en santé
- New funding opportunity for research on the brain!
- New funding opportunity for RNA therapies!
- New funding opportunity for your regenerative research projects
- New GPCR-Specific Biosensor Technology to Monitor Cellular Events Associated with Drugs Efficacy and Side Effects
- New hire Jeanne Ouellet-Ayotte, Marketing & Communication Coordinator
- New hire Xavier Linker, new Director of Strategic Initiatives
- New Network Member: Simmunome
- New partnership with ADRIQ.
- New partnership with Axelys.
- New partnership with Centech.
- New partnership with IVADO.
- New partnership with the Canada Foundation for Innovation via its Research Facilities Navigator.
- New Processes Mimicking the Spray drying technique for the Preparation of Thermally Stable Vaccines
- NEW PROGRAM: SYNERGIQC
- Non-Invasive Diagnostic Test Using Electroretinography for Profiling Patients with Schizophrenia and Bipolar Disorders
- Nouveau partenariat avec BIOQuébec.
- Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer
- Novel in silico-assisted Platform to Rapidly Enhance Specificity and Affinity of Therapeutic Antibodies Against Their Targets
- Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
- Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
- Novel Non-Invasive Laser-Assisted Intraocular Drug Delivery System for an Efficient and Selective Gene Transfer Therapy
- Novel p53-activiting MDM2 inhibitor oncology platform therapy
- nplex-McGill partnership selected by CQDM for a $1M grant to apply next-generation ELISA in drug discovery
- OCE and OBI are partnering with CQDM to the tune of 3 million dollars in innovative inter-provincial drug discovery programs.
- Opportunity of Biopharma Networking during the “Connect-Bio: Médecine personnalisée” event in 22 days.
- Optimizing the monitoring of patients with DLBCL
- Outside the box in neuroscience: CQDM and Brain Canada partner to fund breakthrough technologies to accelerate drug discovery
- Parkinson's disease: a first research collaboration between CQDM and Massachusetts
- PARTENAR-IA - * New * Grants for IA research projects applied to the biopharmaceutical sector
- Partnership agreement between CQDM and Alsace BioValley
- Patrick Wier and Jorge Puente appointed to CQDM’s Board of Directors
- Personalized medicine: CQDM and CIHR fund two promising research collaborations aligning academic and industrial research
- Personalized medicine: CQDM partners with CIHR to accelerate drug discovery across Canada
- Pfizer Canada renews its support to CQDM with a $550,000 contribution
- Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment
- Philip Tagari Appointed to CQDM’s Board of Directors
- Philippe Walker appointed Member of the Scientific Advisory Board of CQDM
- Philippe Walker is appointed chairman of CQDM’s Strategic Orientation Committee
- Photo-album of our event on November 26th, 2008
- Platform for the enrichment of circulating tumor cells (CTCs) for characterization and sensitivity to anti-cancer drugs
- Platform to target small-molecule therapeutics to bone – Novel prodrugs to selectively deliver therapeutics to bone
- Postponed deadline to submit a SynergiQc project
- Pre-budget Consultations: 3 proposals from CQDM to boost Quebec's economy
- Pre-clinical design of a novel targeted and personalized treatment against Sortilin-positive triple negative breast cancers
- Pre-launch of a new call for proposals in June 2020: discover the latest updates!
- Preclinical assessment of aspartyl protease inhibitors as an antifungal therapeutic strategy
- Predict lung cancer risk.
- Press Release: Michele D’Elia and Pierre Côte Join CQDM’s Board of Directors.
- Project funded through CQDM will explore potential of Fusion Genomics’ ONETest™ to improve diagnosis of respiratory tract infections
- PROJECT MANAGER
- Prospective evaluation of the ONETest™ targeted metagenomic platform to identify respiratory tract pathogens for precise diagnosis and clinical trial recruitment
- Proud to announce Veronique is now chief of operations COO at CQDM
- Public/Private Partnerships and New Models to Stimulate Innovation: Examples from Quebec and Massachusetts
- PulmoBind: A Biomarker for Diagnosing Pulmonary Hypertension
- PulmoBind: A New Non-Invasive Marker for the Early Diagnosis of Patients with Pulmonary Hypertension
- Quantum Leap - Program Opened
- Quebec announces an investment of $9 Million for CQDM
- Québec Launches AReNA to Become a Global Leader in RNA Therapies
- Québec Research and Innovation Investment Strategy 2022-2027
- QUO2 MRI: Quantitative Measurement of Metabolic and Vascular Anomalies in the Brain of Alzheimer’s Disease Patients
- RecyTag technology for extended half-lives of small biologics
- Rémi Quirion joins the CQDM Board
- Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers
- Research project
- Richard Fajzel appointed new Chairman of CQDM’s Board of Directors
- SAVE THE DATE / Bio+ech Connec+ event taking place on Wednesday March 16th
- Scientific days of the CRCHUM.
- Selectomics to monitor and predict the emergence of resistance to antibiotics by using the human microbiome
- SEVEN EXCEPTIONAL GRADUATES HONORED BY THE SCHOOL
- SEVEN GRADUATES WHO MAKE ESG UQAM PROUD
- ShARP: Screenable Assays for RNA-Binding Proteins Involved in Brain Disorders
- Six new drug discovery acceleration projects supported by CQDM and Ontario Centres of Excellence showcase continued success of Quebec-Ontario Life Sciences Corridor
- Subscribe to our newsletters
- Success of a preclinical study against breast cancer.
- Supporting innovation is essential to our prosperity
- Sweet Biopharma Day’s 3rd Edition | Québec, Canada Call for startup proposals, now open
- SynergiQc-International: New funding opportunity for public-private biopharmaceutical research
- Synthetic lethality platform to discover, test and validate new therapeutic treatment options for cancer
- Targeting the Right Cells: Human MiniPromoters for Restricted Gene Expression in Specific Cells of the Eyes
- Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine
- The 10th anniversary of CQDM.
- The 4th edition of the innovative partnership forum organized by the CQDM and Montréal InVivo was a huge success
- The Canadian Cancer Society, CQDM, the Cole Foundation and Oncopole grant close to $8.5 million to four researchers in Quebec to support pediatric cancer research
- The Canadian Cancer Society, the Quebec Breast Cancer Foundation and CQDM join forces to fight breast cancer
- The CCS, CQDM and biotech companies will invest nearly $10M to support 3 breast cancer research projects
- The CQDM and Univalor have announced a collaboration agreement
- The CQDM joins Genome Québec and the Ontario Genomics Institute for a partnering event in Toronto
- The CQDM launches its first call for proposals
- The Encapsulated Liver Tissue as a treatment for acute liver failure: proof-of-concept efficacy and safety in large animals using liver organoids composed of primary cells
- The eye: a window to the brain – Detection of Alzheimer’s Disease in the Prodromal Stage from Non-Invasive Hyperspectral Retinal Images
- The first CQDM funded project is a remarkable success – Thanks to CQDM funding, Medicago announces an important investment in Québec
- The French BIO-clusters Lyonbiopole and Alsace BioValley and CQDM join forces to foster R&D collaboration and emergence of France-Quebec projects
- The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala
- Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers
- Three new appointments to CQDM
- To see and hear...souvenir video of our 15th anniversary
- Topic nanovectors for targeted gene therapy of cutaneous psoriasis
- Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers
- Treatment of Hirschsprung disease by rectal administration of neurotrophic factors.
- TRIple negative breast Cancer markers In liquid biopsies using Artificial intelligence (TRICIA study)
- Unlocking a class of challenging drug targets using a next generation screening and lead development platform technology
- Unprecedented mobilization of Quebec's research and innovation ecosystem against COVID-19
- Using Patient’s Blood to Develop a Sensory Neuron-Based Platform to Treat Chemotherapy-Induced Peripheral Neuropathy
- Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM’s Board of Directors
- Validation of KQ-791 in combination immunotherapies cancer models
- VIPER, the lentiviral IPPER platform for drug discovery in trafficking diseases. IPPER-accelerated development of pharmacological correctors for cystic fibrosis
- VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles
- Wallonia (Belgium) and Canada join forces in a new international initiative to improve biopharmaceutical R&D
- We are hiring! Manager – Communications & events - Apply now!
- We are hiring! Project Manager - Apply now!
- We are looking for the winning formula: administrative coordinator position
- We are looking for the winning formula: Communications and Marketing Coordinator
- We are looking for the winning formula: job offer! ACCOUNTING TECHNICIAN
- We are looking for the winning formula: job offer! ADMINISTRATIVE ASSISTANT
- We are looking for the winning formula: job offer! CHIEF ACCOUNTANT
- We are looking for the winning formula: job offer! FINANCIAL CONTROLLER
- We are looking for the winning formula: job offer! Project manager
- We are looking for the winning formula: job offer! SENIOR BUSINESS DEVELOPMENT POSITION, PHARMACEUTICAL PROGRAMS
- We are RECRUITING for a Communication position: Director of Communications and Public Relations - CQDM (Deadline to apply: January 27th)
- We are RECRUITING: General Director for Early Stage Clinical Trial
- We are RECRUITING! Interested in a Controller position? Apply now!
- We are RECRUITING! Interested in a Controller position? Apply now!
- We need your precious collaboration
- Welcome Annie Bernier.
- Welcome Aren!
- Welcome Catherine-Alexandra.
- Welcome Dorothy!
- Welcome to Julia Serafino
- Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support
- Zebrafish High Throughput Screening Platforms for Nuclear Receptor-Related Drug Discovery and Pathway Elucidation
- Privacy Policy
- Terms of Use